T&R Biofab Statistics

Total Valuation

T&R Biofab has a market cap or net worth of KRW 109.67 billion. The enterprise value is 145.35 billion.

Market Cap	109.67B
Enterprise Value	145.35B

Important Dates

The next estimated earnings date is Friday, August 22, 2025.

Earnings Date	Aug 22, 2025
Ex-Dividend Date	n/a

Share Statistics

T&R Biofab has 21.55 million shares outstanding.

Current Share Class	21.55M
Shares Outstanding	21.55M
Shares Change (YoY)	n/a
Shares Change (QoQ)	+1.63%
Owned by Insiders (%)	26.75%
Owned by Institutions (%)	15.09%
Float	15.78M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	11.38
PB Ratio	5.14
P/TBV Ratio	6.09
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-27.30
EV / Sales	15.08
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-9.86

Financial Position

The company has a current ratio of 0.56, with a Debt / Equity ratio of 2.18.

Current Ratio	0.56
Quick Ratio	0.35
Debt / Equity	2.18
Debt / EBITDA	n/a
Debt / FCF	-3.15
Interest Coverage	-5,090.80

Financial Efficiency

Return on equity (ROE) is -20.28% and return on invested capital (ROIC) is -11.59%.

Return on Equity (ROE)	-20.28%
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	-11.59%
Return on Capital Employed (ROCE)	-24.19%
Revenue Per Employee	103.67M
Profits Per Employee	-57.25M
Employee Count	93
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -21.53% in the last 52 weeks. The beta is 0.88, so T&R Biofab's price volatility has been lower than the market average.

Beta (5Y)	0.88
52-Week Price Change	-21.53%
50-Day Moving Average	4,778.80
200-Day Moving Average	5,096.05
Relative Strength Index (RSI)	53.25
Average Volume (20 Days)	120,691

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, T&R Biofab had revenue of KRW 9.64 billion and -5.32 billion in losses. Loss per share was -246.20.

Revenue	9.64B
Gross Profit	2.41B
Operating Income	-13.44B
Pretax Income	-5.32B
Net Income	-5.32B
EBITDA	-10.30B
EBIT	-13.44B
Loss Per Share	-246.20

Full Income Statement

Balance Sheet

The company has 13.18 billion in cash and 46.49 billion in debt, giving a net cash position of -33.31 billion or -1,545.97 per share.

Cash & Cash Equivalents	13.18B
Total Debt	46.49B
Net Cash	-33.31B
Net Cash Per Share	-1,545.97
Equity (Book Value)	21.32B
Book Value Per Share	879.99
Working Capital	-16.83B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -12.86 billion and capital expenditures -1.88 billion, giving a free cash flow of -14.74 billion.

Operating Cash Flow	-12.86B
Capital Expenditures	-1.88B
Free Cash Flow	-14.74B
FCF Per Share	-684.14

Full Cash Flow Statement

Margins

Gross margin is 24.95%, with operating and profit margins of -139.45% and -55.22%.

Gross Margin	24.95%
Operating Margin	-139.45%
Pretax Margin	-55.22%
Profit Margin	-55.22%
EBITDA Margin	-106.85%
EBIT Margin	-139.45%
FCF Margin	n/a

Dividends & Yields

T&R Biofab does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-4.85%
FCF Yield	-13.44%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on April 5, 2022. It was a forward split with a ratio of 2.

Last Split Date	Apr 5, 2022
Split Type	Forward
Split Ratio	2

Scores

T&R Biofab has an Altman Z-Score of -1.67. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.67
Piotroski F-Score	n/a